In this informative video, Prof. Dr. Gontran Verset, an expert in digestive oncology from the Université Libre de Bruxelles, shares the latest findings from various studies presented in the poster discussion session on gastric, pancreatic, and hepatobiliary cancer.
These studies include the KEYNOTE-859 study on pembrolizumab combined with chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer, as well as the phase 2 DisTinGuish study on DKN-01 in combination with tislelizumab + chemotherapy as first-line therapy for patients with advanced gastric adenocarcinoma.
Prof. Verset also discusses two studies on advanced biliary tract cancer, including the SAGC study – a phase 2 randomized, open-label multicenter study on sintilimab and anlotinib, in combination with gemcitabine plus cisplatin as first-line therapy, and a study evaluating neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX. We hope you find this video informative and helpful.
With the educational support of:
